Advertisement
Screener

CYCLERION THERAPEUTICS, INC. (CYCN) Proceeds from Contributed Capital

2.8 / 5 stars · 68/120 Roast Me

CYCLERION THERAPEUTICS, INC. Proceeds from Contributed Capital

CYCLERION THERAPEUTICS, INC. (CYCN) reported Proceeds from Contributed Capital of $46.44 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-02-25.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromContributedCapital · last filed 2021-02-25

  • CYCLERION THERAPEUTICS, INC. proceeds from contributed capital for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
  • CYCLERION THERAPEUTICS, INC. proceeds from contributed capital for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
  • CYCLERION THERAPEUTICS, INC. proceeds from contributed capital for the quarter ending 2019-06-30 was $10.35M, a 54.82% decline year-over-year.
  • CYCLERION THERAPEUTICS, INC. proceeds from contributed capital for the quarter ending 2019-03-31 was $36.09M, a 35.70% increase year-over-year.
  • CYCLERION THERAPEUTICS, INC. proceeds from contributed capital for fiscal 2019 was $46.44M, a 53.99% decline from fiscal 2018.
  • CYCLERION THERAPEUTICS, INC. proceeds from contributed capital for fiscal 2018 was $100.94M.
Period endProceeds from Contributed Capital 3 monthProceeds from Contributed Capital 6 monthProceeds from Contributed Capital 9 monthProceeds from Contributed Capital 12 month
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$0.00
derived: sum of 2 quarters · filed 2021-02-25
$10.35M
derived: sum of 3 quarters · filed 2021-02-25
$46.44M
10-K · filed 2021-02-25
2019-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$10.35M
derived: sum of 2 quarters · filed 2020-11-05
$46.44M
10-Q · filed 2020-11-05
$71.41M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$10.35M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03
$46.44M
10-Q · filed 2020-08-03
$71.41M
derived: sum of 3 quarters · filed 2020-08-03
$97.87M
derived: sum of 4 quarters · filed 2020-08-03
2019-03-31$36.09M
10-Q · filed 2020-05-04
$61.05M
derived: sum of 2 quarters · filed 2020-05-04
$87.52M
derived: sum of 3 quarters · filed 2020-05-04
$110.44M
derived: sum of 4 quarters · filed 2020-05-04
2018-12-31$24.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$51.43M
derived: sum of 2 quarters · filed 2020-03-12
$74.35M
derived: sum of 3 quarters · filed 2020-03-12
$100.94M
10-K · filed 2020-03-12
2018-09-30$26.46M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$49.38M
derived: sum of 2 quarters · filed 2019-11-12
$75.97M
10-Q · filed 2019-11-12
2018-06-30$22.92M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12
$49.51M
10-Q · filed 2019-08-12
2018-03-31$26.59M
10-Q · filed 2019-05-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Lipocine Inc. (LPCN)United States$0.017B-1.79